CJC-1295 · The Long‑Acting GHRH Analog

🧬 CJC-1295

The Long‑Acting GHRH Analog · Mechanism, Human Data, and Regulatory Reality
TL;DR · CJC‑1295 is a synthetic analog of growth hormone‑releasing hormone (GHRH) designed to stimulate the pituitary gland to release more of your own growth hormone (GH) [citation:1][citation:2]. A 2006 Phase 1 trial showed a single dose increased GH by 2‑ to 10‑fold and IGF‑1 by 1.5‑ to 3‑fold for up to 11 days [citation:5][citation:11]. The key distinction is DAC vs. no‑DAC: the DAC version binds to albumin and has a ~8‑day half‑life, while no‑DAC (Mod GRF 1‑29) has a ~30‑minute half‑life and mimics natural pulses [citation:6][citation:12]. As of April 2026, CJC‑1295 is classified as an FDA 503A Category 2 prohibited substance in the U.S. and is banned by WADA [citation:3]. No Phase 2/3 efficacy trials have been completed; long‑term safety remains unknown [citation:1][citation:3].

📑 Contents

What Is CJC‑1295? The DAC Distinction Mechanism of Action Human Clinical Evidence Potential Benefits Safety & Risks Regulatory Status FAQs Disclosure & Disclaimer

What Is CJC‑1295?

CJC‑1295 is a synthetic peptide analog of growth hormone‑releasing hormone (GHRH), a 44‑amino‑acid hypothalamic peptide that drives pulsatile GH secretion from the anterior pituitary [citation:2][citation:4]. It is not growth hormone itself—it is a secretagogue, meaning it signals your pituitary gland to produce and release more of your own natural GH [citation:1][citation:2].

The peptide was originally developed by ConjuChem Biotechnologies in the early 2000s. Its design includes four amino acid substitutions that improve resistance to enzymatic degradation, plus a unique modification—the Drug Affinity Complex (DAC)—that extends its half-life from minutes to days [citation:10][citation:12].

🧬 “CJC‑1295 doesn’t give you growth hormone—it asks your pituitary to make more. That distinction is everything.”

The DAC Distinction: Two Different Compounds

The most critical fact about CJC‑1295 is that there are two distinct versions with profoundly different pharmacokinetics [citation:1][citation:6].

🧪 CJC‑1295 with DAC
Half‑life: ~6–8 days [citation:3][citation:6]
Dosing: 1–2 injections per week [citation:6][citation:9]
GH Pattern: Sustained, gradual “bleed” of GH and IGF‑1 [citation:1][citation:6]
Key feature: DAC binds covalently to serum albumin, protecting the peptide from rapid clearance [citation:8][citation:10]
⚡ CJC‑1295 without DAC (Mod GRF 1‑29)
Half‑life: ~30 minutes [citation:1][citation:6]
Dosing: 1–3 times daily [citation:6][citation:12]
GH Pattern: Sharp, natural‑like pulsatile release [citation:1][citation:6]
Key feature: More closely mimics the body’s natural GHRH rhythm; often stacked with a GHRP [citation:4][citation:9]

The DAC technology is a covalent linker that attaches the peptide to albumin, the most abundant protein in blood plasma. This creates a stable complex that protects CJC‑1295 from enzymatic degradation and renal clearance, extending its half‑life dramatically [citation:8][citation:10].

⚡ “DAC vs. no‑DAC is not a minor detail—it’s the difference between a week‑long GH elevation and a 30‑minute pulse.”

Mechanism of Action

CJC‑1295 works by binding to GHRH receptors (GHRH‑R) on somatotroph cells in the anterior pituitary gland. This activates the Gs/cAMP/PKA signaling cascade, triggering the synthesis and release of growth hormone into the bloodstream [citation:1][citation:8].

Once released, GH travels to the liver and peripheral tissues, stimulating the production of Insulin‑like Growth Factor 1 (IGF‑1), which mediates most of GH’s anabolic effects—including muscle protein synthesis, tissue repair, and cell proliferation [citation:1][citation:2].

  • Pulsatility preserved: Even with the long‑acting DAC version, GH continues to be released in discrete pulses—not as a continuous flood. This is clinically important, as continuous GH elevation tends to cause more insulin resistance and receptor downregulation [citation:1][citation:4].
  • Negative feedback respected: High IGF‑1 levels can still trigger the hypothalamus to release somatostatin, which partially inhibits further GH release. This is a key safety difference from injecting synthetic HGH, which completely bypasses the pituitary and suppresses natural production [citation:1].
  • Synergy with GHRPs: When combined with a growth hormone‑releasing peptide (GHRP) like ipamorelin—which activates the ghrelin receptor—the two pathways (GHRH + ghrelin) produce a larger, more physiologic GH pulse than either alone [citation:4][citation:9].
🔬 “CJC‑1295 works with your biology—not against it. That’s the promise of secretagogues.”

Human Clinical Evidence

The foundational human data for CJC‑1295 come from two Phase 1 trials published in the Journal of Clinical Endocrinology & Metabolism in 2006 [citation:5][citation:11].

📊
GH Elevation
2‑ to 10‑fold increase for ≥6 days after a single injection [citation:5][citation:11]
📈
IGF‑1 Elevation
1.5‑ to 3‑fold increase for 9–11 days; up to 28 days with multiple doses [citation:5][citation:11]
⏳
Half‑Life
5.8–8.1 days (with DAC) [citation:5][citation:11]
🧪
Trial Design
Randomized, placebo‑controlled, double‑blind; 21–61 year old healthy adults [citation:5][citation:11]
🛡️
Safety
No serious adverse reactions reported in Phase 1 [citation:5][citation:11]
🚧
Limitation
No completed Phase 2 or 3 efficacy trials exist [citation:3][citation:14]

It is critical to note that no Phase 2 or Phase 3 trials have been completed for any indication [citation:3][citation:14]. While the Phase 1 data confirmed that CJC‑1295 powerfully engages the GH axis, functional outcomes—such as muscle growth, fat loss, or recovery—have not been demonstrated in controlled human trials [citation:1][citation:3].

📉 “The evidence proves CJC‑1295 raises GH and IGF‑1. It does not prove it builds muscle, burns fat, or improves performance.”

Potential Benefits

Based on the known downstream effects of GH and IGF‑1, CJC‑1295 is theorized to offer several benefits—though direct clinical proof in humans is lacking [citation:1][citation:2].

  • Body Composition: GH stimulates lipolysis (fat breakdown) and protein synthesis. Some users report improvements in fat‑to‑muscle ratio over 3–6 months [citation:2][citation:9].
  • Recovery & Repair: GH is a primary driver of tissue repair and cellular regeneration. This is why it’s often used in recovery and anti‑aging contexts [citation:1][citation:2].
  • Sleep Quality: The majority of natural GH secretion occurs during slow‑wave sleep. Patients often report deeper, more restorative sleep within weeks of starting therapy [citation:1][citation:2].
  • Skin, Bone, & Cognition: IGF‑1 supports collagen production, bone density, and cognitive function. Some clinics use CJC‑1295 as part of longevity protocols [citation:2][citation:10].

However, these are extrapolations from GH biology—not conclusions from CJC‑1295 clinical trials. As one review puts it: “The link is, at present, theoretical and based on the known downstream effects of GH and IGF‑1” [citation:1].

💡 “Potential ≠ proven. CJC‑1295 has theoretical benefits—but the evidence is still in the ‘may’ category.”

Safety & Risks

The Phase 1 trials reported no serious adverse reactions, and CJC‑1295 was “safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg” [citation:5][citation:11]. However, several important caveats exist.

📋 Reported Side Effects

  • Injection site reactions: Transient pain, redness, swelling, induration—the most common AE [citation:1][citation:15].
  • Flu‑like symptoms, headaches, flushing: Reported in some patients [citation:15].
  • Water retention (edema): Elevated GH can cause sodium and water retention, leading to mild swelling in hands and feet [citation:1].
  • Paresthesia: Numbness or tingling, similar to carpal tunnel syndrome, from nerve compression [citation:1].
  • Irritability, anxiety, nausea: Less common but reported [citation:15].

⚠️ Long‑Term & Theoretical Risks

  • Insulin Resistance: GH has a counter‑regulatory effect on insulin. Chronic GH elevation may impair glucose tolerance [citation:1].
  • Cancer Risk: IGF‑1 is a mitogen—it stimulates cell division. Chronically elevated IGF‑1 could potentially accelerate the growth of pre‑existing cancers. This is theoretical, but a known area of concern [citation:1][citation:14].
  • Pituitary Desensitization: Continuous GHRH receptor stimulation may cause receptor downregulation over time—though this was not observed in the short‑term trials [citation:1].
  • One Death in Phase 2: In a 2006 Phase 2 HIV/lipodystrophy trial, one patient died of a myocardial infarction approximately two hours after receiving CJC‑1295. The attending physician deemed it unrelated to treatment, attributing it to pre‑existing coronary artery disease [citation:15].
⚠️ “Short‑term safety data is reassuring. Long‑term safety is completely unknown. That’s a significant gap.”

Regulatory Status

CJC‑1295 occupies a complex regulatory position in 2026.

  • FDA Not Approved: CJC‑1295 has never held an FDA‑approved drug indication for any condition [citation:3][citation:14].
  • FDA 503A Category 2: As of April 2026, CJC‑1295 is classified as a Category 2 bulk drug substance—meaning compounding is prohibited under Section 503A pending further FDA review [citation:3][citation:4].
  • WADA Prohibited: CJC‑1295 is on the 2026 WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), banned both in‑ and out‑of‑competition [citation:3][citation:14].
  • No Pharmacopeia Monograph: No listing in USP, EP, JP, or IP [citation:15].
  • Gray‑Market Reality: Despite the regulatory restrictions, CJC‑1295 continues to be sold online as a “research peptide.” These products are unregulated, and their identity, purity, and sterility cannot be guaranteed [citation:14].
⚖️ “CJC‑1295 is not FDA‑approved, not legal for compounding in the U.S., and banned in sport. That is the regulatory reality.”

CJC‑1295 is a scientifically interesting peptide with a clear mechanism and Phase 1 human data confirming its ability to stimulate GH and IGF‑1. However, the absence of Phase 2/3 efficacy trials, the unknown long‑term safety profile, and its current regulatory status (FDA Category 2, WADA‑banned) make it a compound in limbo. For anyone considering its use, the evidence does not yet support it as a proven therapy for fat loss, muscle growth, or recovery—and the unregulated “research” market carries significant risks.

❓ FAQs About CJC‑1295

What is CJC‑1295?
A synthetic analog of growth hormone‑releasing hormone (GHRH) that stimulates the pituitary gland to release more of your own growth hormone [citation:2][citation:4].
What is the difference between CJC‑1295 with DAC and without DAC?
DAC extends the half‑life to ~8 days (sustained GH elevation). No‑DAC (Mod GRF 1‑29) has a ~30‑minute half‑life and produces a short, natural‑like pulse [citation:1][citation:6].
Does CJC‑1295 work for weight loss or muscle growth?
Theoretical, based on GH/IGF‑1 biology—but direct human evidence is lacking. No Phase 2/3 trials have been completed [citation:1][citation:3].
Is CJC‑1295 FDA‑approved?
No. It has never held an FDA‑approved indication. As of April 2026, it is classified as FDA Category 2, restricting compounding [citation:3].
Is CJC‑1295 legal?
It is not legal for compounding in the U.S. under 503A. It is also banned by WADA in sport [citation:3][citation:14].
What are the side effects of CJC‑1295?
Common: injection site reactions, headaches, flushing, water retention. Theoretical long‑term: insulin resistance, cancer risk, pituitary desensitization [citation:1][citation:15].
Can I buy CJC‑1295 online?
Some websites sell “research peptides,” but these are unregulated—no guaranteed identity, purity, or sterility. Legitimate compounding is currently restricted in the U.S. [citation:14].

📌 Disclosure & Disclaimer

Disclosure: This article is for educational and informational purposes only. The author has no financial ties to any peptide or supplement companies mentioned. References reflect current scientific literature and regulatory documents, not endorsements.

Disclaimer: This content does not constitute medical advice, diagnosis, or treatment. CJC‑1295 is not FDA‑approved for any indication. Always consult a qualified healthcare provider before starting any peptide or supplement regimen. Unregulated products sold online carry significant risks.

🧪 PS — Follow the Evidence, Not the Hype
CJC‑1295 has a fascinating mechanism and Phase 1 data that show it unequivocally raises GH and IGF‑1. But a mechanism is not medicine. Without Phase 2/3 trials, without FDA approval, and with a Category 2 regulatory status, the evidence does not yet support its use as a therapeutic agent. The fundamentals of metabolic health—nutrition, exercise, sleep, and stress management—remain the most powerful and proven tools available.

Stay curious. Stay skeptical. And always follow the evidence.

Science advances step by step. CJC‑1295 is still waiting for its next step.

✧ Written in service of evidence‑based understanding and scientific integrity ✧